Ektopik Gebelik Olgularında Methotrexatın Tedavi Etkinliğinin Değerlendirilmesi
Amaç:Bu çalışmadaki amacımız ektopik gebelik’ te (EP) medikal tedavi olarak tek doz methotrexat (MTX) tedavisi verilen olguların sonuçlarının değerlendirilmesidir. Materyal ve Metot:Eylül 2016 ile Ağustos 2017 arasında Sağlık Bilimleri Üniversitesi Gazi Yaşargil Eğitim ve Araştırma Hastanesinde tedavi edilen EP olgularında MTX tedavisi uygulanmış olanların tedavi sonuçları retrospektif olarak değerlendirildi. Bulgular:Çalışmanın yapıldığı tarihler arasında EP nedeniyle tedavi edilen 126 olgu çalışmaya dahil edildi. Tek doz MTX tedavisi başlanan olgularda başarı oranı %80, başarısızlık %13.8 ve acil cerrahi oranı %6.2 olarak gerçekleşti. Tek doz MTX uygulaması sonrasında 4 ve 7 günler arsında beta- human chorionic gonadotropin (β-hCG) seviyesinin %15 ten az düşmesi sonucunda başarısız olarak kabul edilen olgularda yapılan 2. doz MTX sonucunda, medikal tedavinin toplam başarı oranı %90.7 olarak gerçekleşirken, bu olguların tümünde tedavi sonrası acil cerrahi oranı %9.3 olarak gerçekleşti. Sonuç:Çalışmamızda uygun endikasyonla MTX tedavisi uygulanan EP olgularında medikal tedavinin başarı oranı %90.7 gibi oldukça yüksek bir oranda gerçekleşmiş olup olguların sadece %9.3 de MTX tedavisi sonrasında acil cerrahi tedavigerekmiştir.
ASSESSMENT OF METHOTREXATE EFFICACY IN THE TREATMENT OF ECTOPIC PREGNANCY
Aim:Our aim in this study was to assess efficacy of single- dose methotrexate (MTX) as medical treatment for ectopic pregnancy (EP) by evaluating the results of patients given this treatment.Materials and Methods:Between September 2016 and August 2017, the treatment outcomes of EP cases treated with MTX at Gazi Yaşargil Training and Research Hospital of Health Sciences University were evaluatedretrospectively.Results:In total, 126 cases treated for EP were evaluated and 65 cases were included in the study. In cases administered a single dose of MTX, the success rate was 80%, the failure rate was 13.8%, and the emergency surgery rate was 6.2%. The overall success rate of the medical treatment was 90.7% for a second dose of MTX. An unsuccessful result was considered as less than a 15% reduction in the beta-human chorionic gonadotropin (β-hCG) level between 4 and 7 days after single dose MTX administration. In all cases, the rate of emergency surgery after treatment was 9.3%.Conclusions:In our study, success rates in patients with EP treated with MTX were 80% after a single dose and as high as 90.7% when a second dose was added.
___
- 1. Kirk E, Bourne T. Ectopic pregnancy. Obstet Gynecol Reprod Med. 2011; 21(7):207–11.
- 2. Stovall TG, McCord ML. Early pregnancy lost and ectopic pregnancy. In: Berek JS, Adashi EY, Hillard PA. Novak’s Gynecology (12th ed). Maryland: Williams & Wilkins,1996;487–523.
- 3. Cunningham FG . Williams Obstetrics (20th ed). New Jersey: Prentice Hall International Inc, 1997; 607–34.
- 4. Condous G. The management of early pregnancy complications. Best Pract Res Clin Obstet Gynaecol. 2004; 18(1):37–57.
- 5. Ackerman TE, Levi CS, Dashefsky SM. Interstitial line: sonographic finding in interstitial (cornual) ectopic pregnancy. Radiology. 1993; 189(1):83–7.
- 6. Schwartz RO, Di Pietro DL. B-hCG as a diagnostic aid for suspected ectopic pregnancy. Obstet Gynecol. 1980; 56(2):197-203.
- 7. Lawlor HK, Rubin BJ. Early diagnosis of ectopic pregnancy. West J Med. 1993; 159(2):195–9.
- 8. Mayor S. Early diagnosis of ectopic pregnancy is essential to reduce deaths, says guideline. BMJ 2016; 355:i5954.
- 9. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a metaanalysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003; 101(4):778–84.
- 10. Sowter MC, Farquhar CM, Petrie KJ, Gudex G. A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy. BJOG. 2001; 108(2):192- 203. 3
- 11. Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006;107(4):399-413
- 12. Tas EE, Akcay GFY, Avsar A. Single-dose methotrexate for the treatment of ectopic pregnancy: Our experience from 2010 to 2015. Pakistan journal of medical sciences. 2017;33(1):13-7.
- 13. Buster JE, Carson SA. Ectopic pregnancy; new advances in diagnosis and treatment. Curr Opinion Obstet Gynecol 1995; 7(3):168–76.
- 14. Lozeau AM, Potter B. Diagnosis and management of ectopic pregnancy. Am Fam Physician. 2005; 72(9):1707–714.
- 15. Rana P, Kazmi I, Singh R, Afzal M, Al-Abbasi F A, Aseeri A, et al. Ectopic pregnancy: a review. Archives of Gynecology and Obstetrics.2013; 288(4): 747-57.
- 16. Nyberg DA, Filly RA, Laing FC, Mack LA, Zarutskie PW. Ectopic pregnancy. Diagnosis by sonography correlated with quantitative HCG levels. J Ultrasound Med. 1987; 6(3):145–50.
- 17. Stika CS. Methotrexate: the pharmacology behind medical treatment for ectopic pregnancy. Clin Obstet Gynecol. 2012; 55(2):433-9.
- 18. Kusgoz AG, Aka N, Coskun ADE, Kose G, Tufekcı EC, Vural F. Risk factors and treatment modalities in ectopic pregnancy cases. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2017; 57(1): 1-5.
- 19. Shalev E, Peleg D, Tsabari A, Romano S, Bustan M. Spontaneous resolution of ectopic tubal pregnancy: natural history. Fertil Steril. 1995; 63(1):15–9.
- 20. Aybatlı A, Kaplan PB, Alicik M, Sayın NC, Yuce MA. Single dose methotrexate in treatment of ectopic pregnancy: Review of 32 cases. Balkan Med J. 2011; 28: 10–3.
- 21. Yenen MC, Dede M, Göktolga Ü, Küçük T, Alanbay İ, Pabuçcu R. Ektopik gebelikte risk faktörleri. Gülhane Tıp Dergisi. 2003; 45(3):244–8.
- 22. Butts S, Sammel M, Hummel A, Chittams J, Barnhart K. Risk factors and clinical features of recurrent ectopic pregnancy: a case control study. Fertil Steril. 2003; 80(6): 1340–4.
- 23. Karaer A, Avşar F A, Batıoğlu S. Risk factors for ectopic pregnancy: a case control study. Aust N Z J Obstet Gynaecol. 2006; 46(6):521–7.
- 24. Bacanakgil H, Unal F, Celik S, Bilgi A, Boran B. The results of risk factors and clinical findings of ectopic pregnancy. İstanbul Tıp Dergisi. 2008; 9(4):182–6.